سعر لانتوس 100وحدة دولية/مل 5 خرطوشات 2024

Lantus insulin glargine 100 units/ml, 5 cartridges (Sanofi); basal insulin for diabetes mellitus.

• Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.Population: Adults and children >=2 yearsEuropean Medicines Agency (EMA)
• To improve glycaemic control in adults and paediatric patients with type 1 diabetes and in adults with type 2 diabetes.Population: Adults and paediatric patients (type 1); adults (type 2)DailyMed (U.S. National Library of Medicine)

• Hypoglycaemia (very common); injection-site reactions and lipohypertrophy (common).International label, same product · European Medicines Agency (EMA)
• US label common adverse reactions include hypoglycaemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, oedema and weight gain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to insulin glargine or any of the excipients.International label, same product · European Medicines Agency (EMA)
• During episodes of hypoglycaemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Not the insulin of choice for diabetic ketoacidosis; intravenous regular insulin is recommended instead.International label, same product · European Medicines Agency (EMA)
• Transferring to another insulin type, brand or origin must be done under strict medical supervision and may require dose changes.International label, same product · European Medicines Agency (EMA)
• Repeated injection into the same site can cause lipodystrophy and localised cutaneous amyloidosis, which may worsen glucose control; rotate sites.International label, same product · European Medicines Agency (EMA)

• A large amount of data on pregnant women (more than 1,000 outcomes) indicates no specific adverse effects of insulin glargine on pregnancy and no malformative or feto/neonatal toxicity; use may be considered if clinically needed.International label, same product · European Medicines Agency (EMA)
• No metabolic effects on the breastfed newborn/infant are anticipated; breastfeeding women may require adjustments in insulin dose and diet.International label, same product · European Medicines Agency (EMA)

• Insulin glargine: Binds the insulin receptor; precipitates after subcutaneous injection, giving slow, prolonged absorption without a pronounced peak; lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.